Kate Broderick, PhD

Inovio Pharmaceuticals

Senior Vice President R&D

Dr Broderick has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA therapeutic animal studies and product development in relation to DNA delivery. Her particular area of focus is infectious diseases with an emphasis on emerging targets and those from a bio-threat potential. On the bio-engineering side, Dr Broderick leads the device design efforts specifically pertaining to tissue delivery and she has been central to the development of Inovio novel prototypes and designs. Dr Broderick leads a diverse team of researches which encompasses early discovery work through to IND enabling studies and she is subsequently involved in the clinical and regulatory development of these products. Dr Broderick has authored and co-authored over 70 peer reviewed article and her group regularly publish their findings and present their work in the public forum at conferences. Due to her expertise in the area, Dr Broderick has been invited to participate in WHO advisory meetings related to DNA vaccines and their delivery.
Dr Broderick is also a co-inventor on multiple patents related to DNA vaccine delivery and is principal investigator on grants, awards and contracts from funding bodies such as The Gates Foundation, NIH, Department of Defense and SBIR. She was recently awarded a contract of $56 million from CEPI to fast-track DNA based vaccine candidates for Lassa and MERS through clinical testing.
Dr Broderick received her PhD from the University of Glasgow in Scotland and performed her post-doctoral research at the University of California, San Diego. She joined Inovio Pharmaceuticals in 2006 where she currently leads a diverse research group focused on enhanced delivery techniques for gene based therapeutics as the Senior Vice President, Preclinical R&D.